ADP Diagnostics is an innovative diagnostics company based in Carrickfergus, Northern Ireland, supplying products to the Clinical Diagnostic Laboratories in both the public and private sectors.
As a science graduate of Ulster University and now with 25 years experience in clinical diagnostics, my goal for ADP Diagnostics is to make it a world leader in supplying speciality quality controls, Drugs of Abuse testing kits and POCT equipment. We work with carefully chosen manufacturers and strive to provide bespoke solutions for our customers. Research & Development, validations and trials are carried out in our own laboratory. The excellent laboratories in our local Belfast hospitals also provide invaluable validation data for our clinical products.
ADP Diagnostics is an ISO 9001:2015 registered company, recognising the quality of our administrative and management systems.
Greg Simpson Bsc.
Managing Director
| TOX-SCREEN 14 PANEL DRUG TEST SYSTEM | ||
| UCP-100 DRUG CUP SYSTEM |
|
Sample collection urine cup Unique 14 Panel 10 minutes to test results Accurate, Precise, Reproducible results On board quality control |
| DIP-CARD URINE TEST |
|
Rapid Test Dip-card Unique 14 Panel Fast. Test results in 10 minutes Easy. 3 step operation Minimal training required |
| UNIQUE 14 PANEL | AMP, BAR, BZO, COC, EDDP, FEN, K2, KET, THC, mAMP, MDMA, OPI, TRA, TCA | MHRA REGISTERED |
| FAST AND RELIABLE | SIMPLE SAMPLE PROTOCOL | AVAILABLE NOW |
19 February 2021
An important indicator of ovarian reserve is a blood test called Anti Mullerian Hormone. It is a very sensitive marker of ovarian reserve used by fertility clinics, with the analysis performed in the Clinical Laboratory.
The ADP Tri-Level anti-Mullerian Hormone (MIS) Quality Control set is designed to monitor the performance of AMH immunoassays. This quality control has been validated against the Roche (ECLIA) immunoassay on the Roche Cobas analysers. This is a new product that enables clinicians to have a 3rd party QC for their laboratories.
The quality control has been developed in conjunction with the Royal Victoria Hospital in Belfast, Northern Ireland. The levels have been chosen to reflect critical clinical cut-off values around 12 pmol/L, a mid assay and an elevated level of 47 pmol/L, to check the linearity of the assay.
Stored frozen, defrosted it is stable for 7 days. The kit contains 2 bottles of each level, 3 levels, and 2 mls per vial ( 2 x 3 x 2ml).
Contact ADP Diagnostics for further information or for more information on our range of niche quality controls click here.
Further references:
References: Clinical Biochemistry Volume 49, Issue 3, February 2016, Pages 260–267
(The 2013 National Institute for Health and Care Excellence (NICE) clinical guideline for fertility and the European Society of HumanReproduction and Embryology (ESHRE) recommend AMH measurement as one method to predict ovarian response to gonadotropin stimulation [12] and [13]. The NICE guideline states that AMH concentration of ≤ 0.75 ng/ml (≤ 5.4 pmol/L) indicates a low ovarian response to stimulation, whereas AMH concentration ≥3.50 ng/ml (≥ 25.0 pmol/L) indicates a high response [12]. It follows that precise and accurate AMH measurement in these intervals is a prerequisite for reliable interpretation of AMH results in a clinical setting)
12 February 2021
PSA Ultra Low Quality Control is a product that we developed in response to numerous requests for a low level control to keep pace with the ever-increasing sensitivity of PSA assays. The control is widely used in Ireland by cancer testing centres as it is ideal for monitoring PSA levels post-prostatectomy.
The control is validated against the Roche immunoassay on the Roche Cobas® analyser.
The ‘PSA: Low level’ control is manufactured as stabilised serum from human origin. The concentrations of the QC have been chosen to ensure optimal assay performance at a critical sensitivity level.
A low level or undetectable PSA level is defined as ≤0.06 ng/mL or 0.02ng/mL by the ‘American Society for therapeutic radiology and oncology consensus panel’. As defined by the intuition it is agreed that a 6-12 month ‘undetectable PSA’ level is a prediction of disease-free survival ‘DFS’. Therefore an ultra-sensitive assay is beneficial.
Reference: Int. J. Radiation Oncology Biol. Phys Vol.37 No.5 pp 1035-1041, 1997
The control is stable up to the expiry date when stored at 2-8°c. When opened the control is stable for a period of 14 days when stored at 2-8°c. The kit size is 10 x 1ml.
Contact us for instrument specific values or further information.
